Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
AVDL Stock Chart & Stats
$21.62
-$0.16(-1.47%)
At close: 4:00 PM EST
$21.62
-$0.16(-1.47%)
Day’s Range― - ―
52-Week Range$6.38 - $23.57
Previous CloseN/A
Volume358.54K
Average Volume (3M)1.34M
Market Cap
$2.11B
Enterprise Value$2.08B
Total Cash (Recent Filing)$91.58M
Total Debt (Recent Filing)$37.38M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Mar 09, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding97,817,590
10 Day Avg. Volume1,119,819
30 Day Avg. Volume1,335,977
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)13.54
Price to Sales (P/S)5.91
P/FCF Ratio-21.32
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue8.36
Enterprise Value/Gross Profit8.85
Enterprise Value/Ebitda205.21
Forecast
1Y Price Target
$21.67Price Target Upside0.23% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.93
Revenue Forecast (FY)$357.33M
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionA salt-free formulation in development for narcolepsy and idiopathic hypersomnia could expand the label and attract additional prescribers if approved by 2028.
Product DifferentiationLumryz's once-nightly formulation offers a convenience advantage over twice-nightly oxybates, which could drive faster adoption among narcolepsy patients and increase market share.
Sales OutlookRecent sell-in and sell-through estimates point to annual sales exceeding $280 million, implying upside to earlier guidance and stronger revenue expectations for the current year.
Bears Say
Bid Rigidity And CVR UncertaintyLundbeck's decision not to raise its offer combined with doubts about CVR payouts reduces the likelihood of significant additional premium for shareholders.
Competitive Bidding DynamicsWith the competing proposals closely matched, a prolonged bidding contest appears unlikely, limiting the chance of a materially higher takeover price.
Regulatory And Shareholder Approval RiskThe proposed acquisition is contingent on shareholder approval and regulatory clearances, creating execution risk that could delay or prevent deal completion.
Avadel Pharmaceuticals News
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $6.38 and its highest was $23.57 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Avadel Pharmaceuticals’s market cap is $2.11B.
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Mar 09, 2026 which is in 25 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.059 by -$0.059.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is 0.05.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 97,817,590 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of $0 in its last earnings report, missing expectations of $0.059. Following the earnings report the stock price went up 0.317%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Currently, no hedge funds are holding shares in AVDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avadel Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.67 (0.23% Upside)
$21.67 (0.23% Upside)
Blogger Sentiment
Bullish
AVDL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
166.58%
12-Months-Change
Fundamentals
Return on Equity
-0.32%
Trailing 12-Months
Asset Growth
26.03%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
AVDL Stock 12 Month Forecast
Average Price Target
$21.67
▲(0.23% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Harrow Health
―
Ownership Overview
1.06% Insiders
13.29% Mutual Funds
0.24% Other Institutional Investors
74.91% Public Companies and Individual Investors